Axsome Therapeutics (AXSM): יחס חוב לטווח קצר להון עצמי

Axsome Therapeutics (AXSM) focuses on developing innovative therapies for CNS disorders, accelerating the launch of medications for migraine and depression. Business scaling is supported by outsourcing production to third-party contractors to optimize inventory. Distribution efficiency through diversified channels ensures high margins, with the current figure standing at 1.05. The price indicator on the chart below visualizes the dynamics of the company's debt load and capital.

For Axsome Therapeutics (AXSM), which scales CNS drug sales via contract manufacturing, the history of the short-term debt-to-equity ratio reflects the efficiency of working capital management without capital expenditures on plants. The current liabilities-to-equity ratio measures liquidity risk: an increase in this metric signals a balance sheet overburdened by debt, which could lead to share dilution and a decline in the asset's investment attractiveness.